EP2004604B1 - Dérivés de phénylpipéridine substitués en tant que modulateurs du récepteur de la mélanocortine-4 - Google Patents

Dérivés de phénylpipéridine substitués en tant que modulateurs du récepteur de la mélanocortine-4 Download PDF

Info

Publication number
EP2004604B1
EP2004604B1 EP07724056A EP07724056A EP2004604B1 EP 2004604 B1 EP2004604 B1 EP 2004604B1 EP 07724056 A EP07724056 A EP 07724056A EP 07724056 A EP07724056 A EP 07724056A EP 2004604 B1 EP2004604 B1 EP 2004604B1
Authority
EP
European Patent Office
Prior art keywords
alkyl
vacuo
added
room temperature
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP07724056A
Other languages
German (de)
English (en)
Other versions
EP2004604A1 (fr
Inventor
Michael Soeberdt
Holger Deppe
Philipp Weyermann
Stephan Bulat
Andreas Von Sprecher
Achim Feurer
Cyrille Lescop
Marco Henneböhle
Sonja Nordhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santhera Pharmaceuticals Schweiz GmbH
Original Assignee
Santhera Pharmaceuticals Schweiz GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santhera Pharmaceuticals Schweiz GmbH filed Critical Santhera Pharmaceuticals Schweiz GmbH
Priority to EP07724056A priority Critical patent/EP2004604B1/fr
Publication of EP2004604A1 publication Critical patent/EP2004604A1/fr
Application granted granted Critical
Publication of EP2004604B1 publication Critical patent/EP2004604B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators.
  • the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R).
  • the agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression.
  • disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression.
  • all diseases and disorders where, the regulation of the MC-4R is involved can be treated with the compounds of the invention.
  • MCs Melanocortins stem from pro-opiomelanocortin (POMC) via proteolytic cleavage. These peptides, adrenocorticotropic hormone (ACTH), a-melanocyte-stimulating hormone ( ⁇ -MSH), ⁇ -MSH and ⁇ -MSH, range in size from 12 to 39 amino acids. The most important endogenous agonist for central MC-4R activation appears to be the tridecapeptide ⁇ -MSH. Among MCs, it was reported that ⁇ -MSH acts as a neurotransmitter or neuromodulator in the brain.
  • ACTH adrenocorticotropic hormone
  • ⁇ -MSH a-melanocyte-stimulating hormone
  • ⁇ -MSH ⁇ -MSH
  • ⁇ -MSH acts as a neurotransmitter or neuromodulator in the brain.
  • MC peptides particularly ⁇ -MSH
  • ⁇ -MSH have a wide range of effects on biological functions including feeding behavior, pigmentation and exocrine function.
  • the biological effects of ⁇ -MSH are mediated by a sub-family of 7-transmembrane G-protein-coupled receptors, termed melanocortin receptors (MC-Rs). Activation of any of these MC-Rs results in stimulation of cAMP formation.
  • MC-Rs melanocortin receptors
  • MC-1R was first found in melanocytes. Naturally occurring inactive variants of MC-1 R in animals were shown to lead to alterations in pigmentation and a subsequent lighter coat color by controlling the conversion of phaeomelanin to eumelanin through the control of tyrosinase. From these and other studies, it is evident that MC-1 R is an important regulator of melanin production and coat color in animals and skin color in human.
  • the MC-2R is expressed in the adrenal gland representing the ACTH receptor. The MC-2R is not a receptor for ⁇ -MSH but is the receptor for the adrenocorticotropic hormone I (ACTH I).
  • the MC-3R is expressed in the brain (predominately located in the hypothalamus) and peripheral tissues like gut and placenta, and knock-out studies have revealed that the MC-3R may be responsible for alterations in feeding behavior, body weight and thermogenesis.
  • the MC-4R is primarily expressed in the brain. Overwhelming data support the role of MC-4R in energy homeostasis. Genetic knock-outs and pharmacologic manipulation of MC-4R in animals have shown that agonizing the MC-4R causes weight loss and antagonizing the MC-4R produces weight gain ( A. Kask et al., "Selective antagonist for the melanocortin-4 receptor (HS014) increases food intake in free-feeding rats," Biochem. Biophys. Res. Commun., 245: 90-93 (1998 )).
  • MC-5R is ubiquitously expressed in many peripheral tissues including white fat, placenta and a low level of expression is also observed in the brain. However its expression is greatest in exocrine glands. Genetic knock-out of this receptor in mice results in altered regulation of exocrine gland function, leading to changes in water repulsion and thermoregulation. MC-5R knockout mice also reveal reduced sebaceous gland lipid production ( Chen et al., Cell, 91: 789-798 (1997 )).
  • MC-3R and MC-4R modulators have potent physiological effects besides their role in regulating pigmentation, feeding behavior and exocrine function.
  • ⁇ -MSH recently has been shown to induce a potent anti-inflammatory effect in both acute and chronic models of inflammation including inflammatory bowel-disease, renal ischemia/reperfusion injury and endotoxin-induced hepatitis.
  • Administration of ⁇ -MSH in these models results in substantial reduction of inflammation-mediated tissue damage, a significant decrease in leukocyte infiltration and a dramatic reduction in elevated levels of cytokines and other mediators to near baseline levels.
  • ⁇ -MSH anti-inflammatory actions of ⁇ -MSH are mediated by MC-1R.
  • the mechanism by which agonism of MC-1R results in an anti-inflammatory response is likely through inhibition of the pro-inflammatory transcription activator, NF- ⁇ B.
  • NF- ⁇ B is a pivotal component of the pro-inflammatory cascade, and its activation is a central event in initiating many inflammatory diseases.
  • anti-inflammatory actions of ⁇ -MSH may be, in part, mediated by agonism of MC-3R and/or MC-5R.
  • MC-4R signaling is important in mediating feeding behavior ( S.Q. Giraudo et al., "Feeding effects of hypothalamic injection of melanocortin-4 receptor ligands," Brain Research, 80: 302-306 (1998 )).
  • Further evidence for the involvement of MC-Rs in obesity includes: 1) the agouti (A vy ) mouse which ectopically expresses an antagonist of the MC-1 R, MC-3,R and MC-4R is obese, indicating that blocking the action of these three MC-R's can lead to hyperphagia and metabolic disorders; 2) MC-4R knockout mice ( D.
  • MC-4R appears to play a role in other physiological functions as well, namely controlling grooming behavior, erection and blood pressure.
  • Erectile dysfunction denotes the medical condition of inability to achieve penile erection sufficient for successful intercourse.
  • the term "impotence" is often employed to describe this prevalent condition.
  • Synthetic melanocortin receptor agonists have been found to initiate erections in men with psychogenic erectile dysfunction ( H. Wessells et al., "Synthetic Melanotropic Peptide Initiates Erections in Men With Psychogenic Erectile Dysfunction: Double-Blind, Placebo Controlled Crossover Study", J. Urol., 160: 389-393, (1998 )).
  • Activation of melanocortin receptors of the brain appears to cause normal stimulation of sexual arousal.
  • Evidence for the involvement of MC-R in male and/or female sexual dysfunction is detailed in WO 00/74679 .
  • Diabetes is a disease in which a mammal's ability to regulate glucose levels in the blood is impaired because the mammal has a reduced ability to convert glucose to glycogen for storage in muscle and liver cells. In Type I diabetes, this reduced ability to store glucose is caused by reduced insulin production.
  • Type II diabetes or “Non-Insulin Dependent Diabetes Mellitus” (NIDDM) is the form of diabetes which is due to a profound resistance to insulin stimulating or regulatory effect on glucose and lipid metabolism in the main insulin-sensitive tissues, muscle, liver and adipose tissue. This resistance to insulin responsiveness results in insufficient insulin activation of glucose uptake, oxidation and storage in muscle, and inadequate insulin repression of lipolysis in adipose tissue and of glucose production and secretion in liver.
  • NIDDM Non-Insulin Dependent Diabetes Mellitus
  • Hyperinsulemia is associated with hypertension and elevated body weight. Since insulin is involved in promoting the cellular uptake of glucose, amino acids and triglycerides from the blood by insulin sensitive cells, insulin insensitivity can result in elevated levels of triglycerides and LDL which are risk factors in cardiovascular diseases.
  • MC-4R agonists might be useful in the treatment of NIDDM and Syndrome X.
  • the MC4 receptor is also of interest in terms of the relationship to stress and the regulation of emotional behavior, as based on the following findings. Stress initiates a complex cascade of responses that include endocrine, biochemical and behavioral events. Many of these responses are initiated by release of corticotropin-releasing factor (CRF) ( M.J. Owen and C.B. Nemeroff, "Physiology and pharmacology of corticotrophin releasing factor.” Pharmacol. Rev. 43: 425-473 (1991 )).
  • CCF corticotropin-releasing factor
  • MCs melanocortins
  • proopiomelanocortins which stem from proopiomelanocortin by enzymatic processing, mediate important behavioral and biochemical responses to stress and, consequently, stress-induced disorders like anxiety and depression
  • MCL0129 (1-[(S)-2-(4-Fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a Novel and Potent Nonpeptide Antagonist of the Melanocortin-4 Receptor", J. Pharm. Exp. Ther. 304(2), 818-826 (2003 )).
  • the increased body weight in the treated mice is attributable to a larger amount of lean body mass, which mainly consists of skeletal muscle ( D.L. Marks et al. "Role of the central melanocortin system in cachexia.” Cancer Res. 61: 1432-1438 (2001 )).
  • WO 2004/024720 A1 describes piperazine urea derivatives which are selective agonists of the human melanocortin-4 receptor and as such they are claimed to be useful in the treatment of prevention of obesity-related disorders.
  • WO 2005/047253 A1 describes 4,4-disubstituted piperidine derivatives which are postulated to function as melanocortin receptor agonists.
  • Substituted piperidine derivatives are also described in DE 103 00973 which relates to carboxylic acids and esters having a piperidine ring or a piperazine ring as the central core of the molecule and wherein the core is further substituted in the para-position by a 5-7-membered heterocycle, a phenyl ring, a pyridine ring or a thiazole ring. Said rings are optionally substituted by an ester group.
  • the compounds are used in the preparation of a medicament for the treatment of headaches, non-insulin dependent diabetes mellitus (NIDDM), cardiovascularic diseases, morphintolerance, diseases of the skin, inflammations, allergic rhinitis, asthma, diseases with vascular dilatation and, consequently, with reduced blood circulation in tissues, acute or preemptive treatment of menopausal hot flashes of worsen with an estrogen deficiency or for the treatment of pain.
  • NIDDM non-insulin dependent diabetes mellitus
  • novel substituted phenylpiperidine derivatives with improved ability to cross the blood brain barrier, which are useful as melanocortin-4 receptor modulators to treat-cancer cachexia, muscle wasting, anorexia, anxiety, depression, obesity, diabetes, sexual dysfunction and other diseases with MC-4R involvement.
  • the present invention relates to substituted phenylpiperidine derivatives of structural formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and n are defined as described below.
  • the phenylpiperidine derivatives of structural formula (I) are effective as melanocortin receptor modulators and are particularly effective as selective melanocortin-4 receptor (MC-4R) modulators. They are therefore useful for the treatment of disorders where the activation or inactivation of the MC-4R are involved.
  • Agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression.
  • the present invention also relates to pharmaceutical compositions comprising the compounds of the present invention and a pharmaceutically acceptable carrier.
  • the present invention relates to substituted phenylpiperidine derivatives useful as melanocortin receptor modulators, in particular, selective MC-4R agonists and MC-4R antagonists.
  • the compounds of the present invention are represented by structural formula (I) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof, wherein
  • the compounds according to formula (I) adopt the structural conformation of the following stereoisomer formula (I'):
  • R 2 represents Cl or F.
  • the phenyl ring directly connected with the piperidine ring is monosubstituted by a chlorine or fluorine atom in the meta or para-position.
  • R 3 represents H, Cl, or CH 3 , more preferably Cl. In an alternative embodiment, R 3 preferably represents F.
  • R 4 represents Cl
  • the variant R 1 represents -(CH 2 ) l -T or-O-(CH 2 ) m -T.
  • At least one of R 7 and R 8 is selected from C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkinyl and C 2-6 alkylene-O-C 1-6 -alkyl, more preferably from C 2-6 -alkenyl, C 2-6 -alkinyl and C 2-6 -alkylene-O-C 1-6 -alkyl.
  • R 9 is independently selected from halogen, CN, OH, C 1-6 -alkyl optionally substituted with 1 to 3 substituents selected from halogen, CN and OH, and O-C 1-6 -alkyl optionally substituted with 1 to 3 substituents selected from halogen, CN and OH.
  • the variant I is preferably selected from 2 or 3.
  • the variant m is preferably selected from 2, 3 or 4, more preferably from 2 or 3.
  • T is preferably selected from the group consisting of the following radicals:
  • R 5 is preferably selected from the group consisting of
  • Alkenyl is a straight chain or branched alkyl having 2 to 6 carbon atoms and which contains at least one carbon-carbon double bond, such as vinyl, allyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, isopropenyl, pentenyl, or hexenyl.
  • Alkinyl is a straight chain or branched alkyl having 2 to 6 carbon atoms and which contains at least one carbon-carbon triple - bond, such as ethinyl, 1-propinyl, 1-butinyl, 2-butinyl, pentinyl or hexinyl.
  • a 3-7-membered, saturated, unsaturated or aromatic ring containing 0-2 nitrogen atoms encompasses a 3-7-membered saturated carbocycle such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Said term further encompasses 3-7-membered unsaturated carbocycles such as cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclohexa-1,4-diene or cycloheptadienes, or aromatic rings such as benzene.
  • Nitrogen-containing, 3-7-membered, saturated, unsaturated or aromatic heterocycles are further encompassed by the above term. Examples thereof include azetidine, pyrrolidine, piperidine, azepane, piperazine, pyridine, pyrimidine, pyrazine, pyrrole, imidazole, and pyrazole.
  • the compounds of structural formula (I) are effective as melanocortin receptor modulators and are particularly effective as selective modulators of MC-4R. They are therefore useful for the treatment and/or prevention of disorders responsive to the activation and inactivation of MC-4R, such as cancer cachexia, muscle wasting, anorexia, anxiety, depression, obesity, diabetes, sexual dysfunction and other diseases with MC-4R involvement.
  • the compounds of structural formula (I) are particularly useful as antagonists of MC-4R. Thus, they are preferably used for the preparation of a medicament for the treatment and/or prevention of cancer cachexia, muscle wasting, anorexia, anxiety and depression.
  • Compounds of structural formula (I) contain one or more asymmetric centers and can occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of structural formula (I).
  • Compounds of structural formula (I) may be separated into their individual diastereoisomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof, or via chiral chromatography using an optically active stationary phase.
  • Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
  • any stereoisomer of a compound of the general formula (I) may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known absolute configuration.
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids.
  • Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Particularly preferred are the ammonium, calcium, lithium, magnesium, potassium and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
  • basic ion exchange resins such as arginine
  • salts may be prepared from pharmaceutical acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, formic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, malonic, mucic, nitric, pamoic, pantothenic, phosphoric, propionic, succinic, sulfuric, tartaric, p-toluenesulfonic, trifluoroacetic acid and the like.
  • Particularly preferred are citric, fumaric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids.
  • the compounds of formula (I) are melanocortin receptor modulators and as such are useful in the treatment, control or prevention of diseases, disorders or conditions responsive to the inactivation of one or more of the melanocortin receptors including, but not limited to, MC-1 R, MC-2R, MC-3R, MC-4R or MC-5R.
  • diseases, disorders or conditions include, but are not limited to, cancer cachexia, muscle wasting, anorexia, anxiety, depression, obesity (by reducing appetite, increasing metabolic rate, reducing fat intake or reducing carbohydrate craving), diabetes mellitus (by enhancing glucose tolerance, decreasing insulin resistance) and male and female sexual dysfunction (including impotence, loss of libido and erectile dysfunction).
  • the compounds of formulas (I) can be further used in the treatment, control or prevention of hypertension, hyperlipidemia, osteoarthritis, cancer, gall bladder disease, sleep apnea, compulsion, neuroses, insomnia/sleep disorder, substance abuse, pain, fever, inflammation, immune-modulation, rheumatoid arthritics, skin tanning, acne and other skin disorders, neuroprotective and cognitive and memory enhancement including the treatment of Alzheimer's disease.
  • Any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of a compound of the present invention.
  • oral, rectal, topical, parenteral, ocular, pulmonary, nasal and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols and the like.
  • compounds of formula (I) are administered orally or topically.
  • the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
  • the compounds of the present invention are administered at a daily dosage of from about 0.001 milligram to about 100 milligrams per kilogram of body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form.
  • the total daily dose will generally be from about 0.07 milligrams to about 3500 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
  • the compounds of the present invention are administered at a daily dosage of from about 0.001 milligram to about 100 milligrams per kilogram of body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form.
  • the total daily dose will generally be from about 0.07 milligrams to about 3500 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
  • the compounds of the present invention are administered at a daily dosage of from about 0.001 milligram to about 100 milligram per kilogram of animal body weight, preferably given in a single dose or in divided doses two to six times a day, or in sustained release form.
  • the total daily dose will generally be from about 0.07 milligrams to about 3500 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.
  • compounds of the present invention are given in a dose range of 0.001 milligram to about 100 milligram per kilogram of body weight, preferably as a single dose orally or as a nasal spray.
  • the compounds of formula (I) are preferably formulated into a dosage form prior to administration. Accordingly the present invention also includes a pharmaceutical composition comprising a compound of formula (I) and a suitable pharmaceutical carrier.
  • the active ingredient (a compound of formula (I)) is usually mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper or other container.
  • a carrier which may be in the form of a capsule, sachet, paper or other container.
  • the carrier serves as a diluent, it may be a solid, semisolid or liquid material which acts as a vehicle, excipient or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosol (as a solid or in a liquid medium), soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • Suitable carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propylhydroxybenzoates, talc, magnesium stearate and mineral oil.
  • the formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents.
  • the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
  • the preparation of the compounds of the present invention may be carried out via sequential or convergent synthetic routes.
  • the skilled artisan will recognize that, in general, the A and B moieties of a compound of formula (I) are connected via amide bonds. The skilled artist can, therefore, readily envision numerous routes and methods of connecting the two moieties via standard peptide coupling reaction conditions.
  • standard peptide coupling reaction conditions means coupling a carboxylic acid with an amine using an acid activating agent such as EDCI, dicyclohexylcarbodiimide and benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate, in a inert solvent such as DCM, in the presence of a catalyst such as HOBt.
  • an acid activating agent such as EDCI, dicyclohexylcarbodiimide and benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate
  • Protecting groups like Z, Boc and Fmoc are used extensively in the synthesis, and their removal conditions are well known to those skilled in the art.
  • removal of Z groups can he achieved by catalytic hydrogenation with hydrogen in the presence of a noble metal or its oxide, such as palladium on activated carbon in a protic solvent, such as ethanol.
  • a protic solvent such as ethanol.
  • removal of Z can also be achieved by treatment with a solution of hydrogen bromide in acetic acid, or by treatment with a mixture of TFA and dimethylsulfide.
  • Removal of Boc protecting groups is carried out in a solvent such as methylene chloride, methanol or ethyl acetate with a strong acid, such as TFA or HCl or hydrogen chloride gas.
  • the B and C moieties of a compound of formula (I) are linked together via a urea function.
  • the skilled artist can, therefore, readily envision numerous routes and methods of connecting the two moieties using different well known methods.
  • the compounds of formula (I), when existing as a diastereomeric mixture, may be separated into diastereomeric pairs of enantiomers by fractional crystallization from a suitable solvent such as methanol, ethyl acetate or a mixture thereof.
  • a suitable solvent such as methanol, ethyl acetate or a mixture thereof.
  • the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means by using an optically active acid as a resolving agent.
  • any enantiomer of a compound of the formula (I) may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
  • the compounds of formula (I) of the present invention can be prepared according to the procedures of the following schemes and examples, using appropriate materials and are further exemplified by the following specific examples. Moreover, by utilizing the procedures described herein, in conjunction with ordinary skills in the art, additional compounds of the present invention claimed wherein can be readily prepared.
  • the compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention.
  • the examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds.
  • the instant compounds are generally isolated in the form of their pharmaceutically acceptable salts, such as those described previously.
  • the free amine bases corresponding to the isolated salts can be generated by neutralization with a suitable base, such as aqueous sodium hydrogencarbonate, sodium carbonate, sodium hydroxide and potassium hydroxide, and extraction of the liberated amine free base into an organic solvent followed by evaporation.
  • a suitable base such as aqueous sodium hydrogencarbonate, sodium carbonate, sodium hydroxide and potassium hydroxide
  • the amine free base isolated in this manner can be further converted into another pharmaceutically acceptable salt by dissolution in an organic solvent followed by addition of the appropriate acid and subsequent evaporation, precipitation or crystallization. All temperatures are degrees Celsius.
  • Cis-3-aza-bicyclo[3.1.0]hexane hydrochloride was prepared as described in US4,183,857 .
  • the resulting tetrahydropyridine can be hydrogenated in the presence of a catalyst, such as PtO 2 or Pd/C, to yield the protected piperidine.
  • a catalyst such as PtO 2 or Pd/C
  • the piperidine is further reacted with an alkylchloride or alkylbromide bearing the capping group T in the presence of a base such as Cs 2 CO 3 or NaH in an appropriate solvent such as DMF to give the Boc-protected A moiety.
  • the resulting tetrahydropyridine can be hydrogenated in the presence of a catalyst, such as PtO 2 or Pd/C, to yield the protected piperidine.
  • a catalyst such as PtO 2 or Pd/C
  • the methylether can be cleaved with a reagent such as aqueous hydroiodic acid in acetic acid or trimethylsilyl iodide in chloroform, at a suitable temperature to get access to the corresponding phenol as hydroiodide.
  • the Boc-protecting group which is lost during this process, can subsequently be reintroduced by using a reagent such as Boc 2 O in the presence of a base such as DIEA in an appropriate solvent such as DCM or DMF.
  • the Boc-protected piperidine is further reacted with an alkylchloride or alkylbromide bearing the capping group T in the presence of a base such as Cs 2 CO 3 or NaH in an appropriate solvent such as DMF to give the Boc-protected A moiety.
  • the intermediate product from Reaction schemes 1 and 2, optionally substituted 1-Boc-4-(2-hydroxy-phenyl)-piperidine can also be alkylated with an ⁇ -T-capped alkylalcohol in the presence of a reagent such as DEAD or DIAD, and a phosphine such as PPh 3 in a suitable solvent such as THF to give the Boc-protected A moieties.
  • a reagent such as DEAD or DIAD
  • a phosphine such as PPh 3
  • THF suitable solvent
  • the same intermediate can be reacted with an ⁇ -bromo alkylalcohol, using the reaction conditions described above, to give access to the corresponding phenolether which subsequently can be used to alkylate the capping group T in the presence of a suitable base such as K 2 CO 3 or NaH, in an appropriate solvent such as MeCN, THF, or DMF, at a suitable temperature, to yield the Boc-protected A moieties.
  • a suitable base such as K 2 CO 3 or NaH
  • Optionally substituted 2-bromotoluene is brominated with NBS in the presence of a radical starter such as Bz 2 O 2 in an appropriate solvent such as CCl 4 at a suitable temperature to yield the corresponding benzylbromide.
  • the benzylbromide is reacted with optionally substituted diethyl malonate in the presence of a base such as sodium ethoxide in a suitable solvent such as ethanol.
  • Optionally substituted 3-(2-bromophenyl)propionic acid amide can be reacted with 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester in the presence of a base such as K 2 CO 3 and a catalyst such as dichloro(1,1'-bis(diphenylphosphino)-ferrocene)palladium(li) DCM adduct, in an organic solvent such as DMF or toluene, at a suitable temperature to lead to the corresponding tetrahydropyridine.
  • a base such as K 2 CO 3
  • a catalyst such as dichloro(1,1'-bis(diphenylphosphino)-ferrocene)palladium(li) DCM adduct
  • the resulting tetrahydropyridine can be hydrogenated in the presence of a catalyst, such as PtO 2 or Pd/C, to yield the protected piperidine.
  • a catalyst such as PtO 2 or Pd/C
  • the side chain amide function can be reduced using a reagent such as LiAlH 4 or borane-THF complex in an appropriate inert solvent such as diethyl ether or THF at a suitable temperature to yield the Boc-protected A , moiety.
  • Optionally substituted 2'-bromo-cinnamic acid amide can be reacted with 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester in the presence of a base such as K 2 CO 3 and a catalyst such as dichloro(1,1'-bis(diphenylphosphino)-fen-ocene)palladium(II) DCM adduct, in an organic solvent such as DMF or toluene, at a suitable temperature to lead to the corresponding tetrahydropyridine.
  • a base such as K 2 CO 3
  • a catalyst such as dichloro(1,1'-bis(diphenylphosphino)-fen-ocene)palladium(II) DCM adduct
  • the resulting tetrahydropyridine and the cinnamic acid amide double bond can be hydrogenated in the presence of a catalyst, such as PtO 2 or Pd/C, to yield the protected piperidine.
  • a catalyst such as PtO 2 or Pd/C
  • the side chain amide function can be reduced using a reagent such as LiAlH 4 or borane-THF complex in an appropriate inert solvent such as diethyl ether or THF at a suitable temperature to yield the Boc-protected A moiety.
  • optionally substituted 3-(2-bromophenyl)propionic acid is reacted with methanol in the presence of a catalyst such as sulfuric acid to form the corresponding methyl ester.
  • a catalyst such as sulfuric acid
  • 3-(2-bromophenyl)propionic acid ester can be reacted with 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolah-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester in the presence of a base such as K 2 CO 3 and a catalyst such as dichloro(1,1'-bis(diphenylphosphino)-ferrocene)palladium(II) DCM adduct, in an organic solvent such as DMF or toluene, at a suitable temperature to lead to the corresponding tetrahydropyridine.
  • the resulting tetrahydropyridine can be hydrogenated in the presence of a catalyst, such as PtO 2 or Pd/C, to yield the protected piperidine.
  • a catalyst such as PtO 2 or Pd/C
  • the side chain ester function can be reduced using a reagent such as LiAlH 4 or borane-THF complex in an appropriate inert solvent such as diethyl ether or THF at a suitable temperature to yield the corresponding alcohol which can subsequently be oxidized using a reagent such as Dess-Martin periodinane in an appropriate solvent such as DCM or using sulfurtrioxide-pyridine complex with a base such as triethylamine in a suitable solvent such as DCM.
  • Optionally substituted 3-(2-bromophenyl)propionyl aldehyde is reacted with the capping group T in the presence of a reducing agent such as sodium triacetoxyborohydride in an appropriate solvent such as 1,2-dichloroethane to form the corresponding Boc-protected A moiety.
  • a reducing agent such as sodium triacetoxyborohydride
  • an appropriate solvent such as 1,2-dichloroethane
  • the intermediate product from Reaction scheme 6, optionally substituted 3-(2-bromophenyl)propionic acid ester can also be subjected to a Negishi coupling with (1-tert-butoxycarbonylpiperidin-4-yl)(iodo)zinc ( J. Org. Chem. 2004, 69, 5120-5123 ) in the presence of copper(I) iodide and dichloro(1,1'-bis(diphenyl-phosphino)-ferrocene)palladium(li) DCM adduct in an inert solvent such as DMA to yield the resulting phenylpiperidine which can be further processed as shown in Reaction scheme 6.
  • a Negishi coupling with (1-tert-butoxycarbonylpiperidin-4-yl)(iodo)zinc J. Org. Chem. 2004, 69, 5120-5123
  • the resulting tetrahydropyridine can be hydrogenated in the presence of a catalyst, such as PtO 2 or Pd/C, to yield the protected piperidine:
  • a catalyst such as PtO 2 or Pd/C
  • the ester function can then be reduced to the corresponding aldehyde with DIBAL-H in an appropriate solvent such as Et 2 O or THF at a suitable temperature.
  • Reductive amination of the aldehyde with an amine T-H in the presence of a reducing agent such as sodium triacetoxyborohydride in an appropriate solvent such as 1,2-dichloroethane leads to the Boc-protected A moiety.
  • Optionally substituted 2'-bromo-phenylacetic amide can be reacted with 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester in the presence of a base such as K 2 CO 3 and a catalyst such as dichloro(1,1'-bis(diphenylphosphino)-ferrocene)palladium(II) DCM adduct, in an organic solvent such as DMF or toluene, at a suitable temperature to lead to the corresponding tetrahydropyridine.
  • a base such as K 2 CO 3
  • a catalyst such as dichloro(1,1'-bis(diphenylphosphino)-ferrocene)palladium(II) DCM adduct
  • the resulting tetrahydropyridine can be hydrogenated in the presence of a catalyst, such as PtO 2 or Pd/C, to yield the protected piperidine.
  • a catalyst such as PtO 2 or Pd/C
  • the side chain amide function can be reduced using a reagent such as LiAlH 4 or borane-THF complex in an appropriate inert solvent such as diethyl ether or THF at a suitable temperature to yield the Boc-protected A moiety.
  • Optionally substituted 2-bromophenylacetic acid is reduced with sodium borohydride in the presence of a reagent such like boron trifluoride diethyl etherate in an appropriate solvent such as THF at a suitable temperature to yield the corresponding phenylethylalcohol.
  • Reaction of the alcohol with a bromination reagents such as phosphorous tribromide in the presence of a base such as pyridine in an appropriate solvent like toluene at a suitable temperature leads to the phenylethylbromide.
  • the phenethylbromide is reacted with optionally substituted diethyl malonate in the presence of a base such as sodium hydride in a suitable solvent such as THF.
  • Subsequent saponification with a base such as KOH in an appropriate solvent such as water-ethanol mixture followed by a second saponification step with a suitable base such as KOH in a solvent such as water leads to the alkylated malonic acid which is decarboxylated at an appropriate temperature.
  • the product of this reaction is converted to the acid chloride using a reagent such as oxalyl chloride or thionyl chloride in an inert solvent such as DCM with a catalytic amount of DMF, and reacted with the capping group T to form the corresponding amide.
  • a reagent such as oxalyl chloride or thionyl chloride in an inert solvent such as DCM with a catalytic amount of DMF
  • Optionally substituted 3-(2-bromophenyl)butanoic acid amide can be reacted with 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2.yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester in the presence of a base such as K 2 CO 3 and a catalyst such as dichloro(1,1'-bis(diphenylphosphino)-ferrocene)palladium(lI) DCM adduct, in an organic solvent such as DMF or toluene, at a suitable temperature to lead to the corresponding tetrahydropyridine.
  • a base such as K 2 CO 3
  • a catalyst such as dichloro(1,1'-bis(diphenylphosphino)-ferrocene)palladium(lI) DCM adduct
  • the resulting tetrahydropyridine can be hydrogenated in the presence of a catalyst, such as PtO 2 or Pd/C, to yield the protected piperidine.
  • a catalyst such as PtO 2 or Pd/C
  • the side chain amide function can be reduced using a reagent such as LiAlH 4 or borane-THF complex in an appropriate inert solvent such as diethyl ether or THF at a suitable temperature to yield the Boc-protected A moiety.
  • the intermediate product from Reaction schemes 1 and 2, optionally substituted 1-Boc-4-(2-hydroxy-phenyl)-piperidine can also be alkylated with an alcohol which contains a cyclic tertiary amine moiety in the presence of a reagent, such as DEAD or DIAD and a phosphine such as PPh 3 in a suitable solvent such as THF to give the Boc-protected A moieties.
  • a reagent such as DEAD or DIAD
  • a phosphine such as PPh 3
  • an alcohol containing a protected cyclic secondary amine moiety can be introduced as building block using the conditions described above.
  • the protecting group has to be orthogonal to the Boc-protecting group used for protection of the piperidine. After coupling of the A moiety with the B-C moiety this protecting group can be removed using standard methods.
  • the starting material of Boc-protected phenylpiperidine (A moiety) can be deprotected in the presence of TFA/CH 2 Cl 2 , HCl/EtOAc, HCl/dioxane or HCl in MeOH/dioxane with or without a cation scavenger, such as dimethyl sulfide (DMS) before being subjected to the coupling procedure. It can be converted to the free base before being subjected to the coupling procedure or in some cases used as the salt.
  • a cation scavenger such as dimethyl sulfide (DMS)
  • the B-C moieties can be synthesized as shown in Reaction scheme 13.
  • Optionally substituted phenylalanine can be converted to the corresponding methyl ester hydrochloride using an activating reagent such as thionyl chloride or oxalyl chloride in methanol.
  • Amino acid methyl ester hydrochloride can be reacted with a reagent such as triphosgene in the presence of a base such as NaHCO 3 (aq.) in a suitable solvent such as DCM to yield the isocyanate which can subsequently be reacted with an amine R 5 -H in a suitable solvent such as DCM.
  • the ester function can be hydrolyzed with a base such as LiOH in a suitable solvent or solvent mixture such as water/THF/methanol to give access to the B-C-moiety.
  • a moieties can be coupled with B-C moieties in the presence of EDCl/HOBt, a base such as N-methylmorpholine (NMM) and a solvent such as dichloromethane (DCM).
  • a suitable solvent such as DCM, DMF, THF or a mixture of the above solvents, can be used for the coupling procedure.
  • Suitable base include triethylamine (TEA), diisopropylethylamine (DIEA), N-methylmorpholine (NMM), collidine or 2,6-lutidine.
  • TAA triethylamine
  • DIEA diisopropylethylamine
  • NMM N-methylmorpholine
  • collidine or 2,6-lutidine.
  • a base may not be needed when EDCl/HOBt is used.
  • the reaction mixture can be diluted with an appropriate organic solvent, such as EtOAc, DCM or Et 2 O, which is then washed with aqueous solutions, such as water, HCl, NaHSO 4 , bicarbonate, NaH 2 PO 4 , phosphate buffer (pH 7), brine or any combination thereof.
  • an appropriate organic solvent such as EtOAc, DCM or Et 2 O
  • aqueous solutions such as water, HCl, NaHSO 4 , bicarbonate, NaH 2 PO 4 , phosphate buffer (pH 7), brine or any combination thereof.
  • the reaction mixture can be concentrated and then be partitioned between an appropriate organic solvent and an aqueous solution.
  • the reaction mixture can be concentrated and subjected to chromatography without aqueous workup.
  • the product can be transferred to a pharmaceutically acceptable salt such as a hydrochloride, using HCl in a solvent or solvent mixture such as diethyl ether/acetone.
  • a pharmaceutically acceptable salt such as a hydrochloride
  • the three moieties can also be combined stepwise, as shown in Reaction scheme 15.
  • An appropriate A moiety is coupled to a Boc-protected B moiety in the presence of EDCl/HOBt, a base such as N-methylmorpholine (NMM) and a solvent such as dichloromethane (DCM) followed by Boc deprotection with the aid of hydrogen chloride in a mixture of dioxane and methanol.
  • the product can be reacted with 4-nitrophenyl chloroformate in the presence of a base such as NMM in an appropriate solvent such as DCM to yield the 4-nitrophenyl carbamate which subsequently can be treated with an amine H-R 5 in the presence of a base such as DIEA in an appropriate solvent such as THF to give access to the target compound.
  • a base such as NMM
  • DIEA an appropriate solvent
  • THF an appropriate solvent
  • the final product can be converted to a pharmaceutically acceptable salt as described above.
  • 1,1'-carbonyldiimidazole can be reacted with an amine in an appropriate solvent such as THF at a suitable temperature.
  • the product of this reaction is further reacted with methyl iodide in a suitable solvent such as acetonitrile to yield the 1-methyl-3-(amino-1-carbonyl)-3H-imidazol-1-ium iodide.
  • This activated species is reacted with a deprotected A-B moiety in the presence of a base such as triethylamine in a suitable solvent such as THF to yield the final product
  • the final product can be converted to a pharmaceutically acceptable salt as described above.
  • the purified product was dissolved in EtOAc (3.00 ml), treated with 1 M HCl in Et 2 O (633 ⁇ l), and the resulting suspension was diluted with hexane (20 ml). The precipitate was filtered off, washed with hexane (5 ml), and dried in vacuo at room temperature over P 2 O 5 overnight. The product was obtained as a white solid.
  • the purified product was dissolved in ethyl acetate (300 ⁇ l), and treated with 1 M HCl in Et 2 O (26 ⁇ l) followed by hexane (3 ml). The precipitated salt was filtered off, washed with hexane (1 ml), and finally dried in vacuo at room temperature over P 2 O 5 overnight.
  • the purified product was dissolved in DCM and treated with 1 M HCl in Et 2 O (1.27 ml) and evaporated in vacuo. The residue was dissolved in DCM and treated with diethyl ether and hexane. The precipitated salt was filtered off, washed with hexane and diethyl ether, and finally dried in vacuo at 40°C for 2 h.
  • the resulting brown suspension was stirred at room temperature for 1 h and at 40°C for 3 h.
  • the reaction mixture was diluted with EtOAc (300 ml), the organic phase was removed and the aqueous phase was extracted with diethyl ether (3 x 200ml).
  • the combined organic layer was washed with 48% aqueous HBr (2 x 50 ml) followed by water (5 x 100 ml) and brine (70 ml), dried over Na 2 SO 4 and evaporated to give a brown oil.
  • the crude product was purified by distillation. All fractions which distilled of at normal pressure up to 60°C were discarded. Vacuum was applied and the fraction distilling off at 45°C was collected. This fraction was further purified by column chromatography.
  • the purified product was dissolved in ethyl acetate (200 ⁇ l), cooled to 0°C and treated with 1 M HCl in Et 2 O (70 ⁇ l) and treated with diethyl ether (1 ml). The precipitate was filtered off and dried under vacuum over Sicapent. The product was obtained as an off-white solid.
  • the crude product was purified by vacuum distillation employing a 5 cm Vigreux column at a pressure of ca. 15 mbar (with an oil-bath temperature of ca. 120°C). The fraction distilling off at 89-90°C was collected. The product was obtained as a colorless oil.
  • the purified product was dissolved in DCM and treated with 1 M HCl in Et 2 O (73 ⁇ l) and evaporated in vacuo. The residue was dissolved in DCM and the salt was precipitated by addition of Et 2 O and hexane. The precipitate was filtered off, washed with hexane and Et 2 O and dried in vacuo at 40°C for 2 hours. The product was obtained as a white solid.
  • the purified product was dissolved in ethyl acetate (2 ml), treated with 1 M HCl in Et 2 O (200 ⁇ l), and the resulting suspension was diluted with hexane (20 ml). The precipitate was filtered off, washed with hexane and diethyl ether, and dried in vacuo at room temperature over P 2 O 5 overnight. The product was obtained as white solid.
  • the purified product was dissolved in DCM, treated with 1 M HCl in Et 2 O (66 ⁇ l), and the resulting suspension was diluted with diethyl ether and hexane. The precipitate was filtered off, washed with hexane and diethyl ether, and dried in vacuo at room temperature over P 2 O 5 overnight. The product was obtained as a white solid.
  • the purified product was dissolved in ethyl acetate and treated with 1 M HCl in Et 2 O (100 ⁇ l). The product was precipitated by addition of hexane (20 ml). The precipitate was filtered off and dried in vacuo over P 2 O 5 . The product was obtained as white solid.
  • the purified product was dissolved in ethyl acetate and treated with 1 M HCl in Et 2 O (100 ⁇ l). The product was precipitated by addition of hexane (20 ml). The precipitate was filtered off and dried in vacuo over P 2 O 5 . The product was obtained as a white solid.
  • the purified product was dissolved in ethyl acetate (2 ml), treated with 1 M HCl in Et 2 O (200 ⁇ l), and the resulting suspension was diluted with hexane (20 ml). The precipitate was filtered off, washed with hexane and diethyl ether, and dried in vacuo at room temperature over P 2 O 5 overnight. The product was obtained as a white solid.
  • Phosphorous tribromide (3.71 ml) was dissolved in toluene (30 ml) and cooled to 0°C. Then pyridine (1.68 ml) was added: To the suspension thus obtained, a solution of intermediate 44a) (18.6 g) and pyridine (0.56 ml) in toluene (30 ml) was added over 15 min. The cooling bath was removed and stirring was continued at room temperature for 1 h. Then the reaction mixture was heated to 100°C for another hour. The reaction mixture was cooled to ambient temperature, diluted with EtOAc (300 ml) and washed with water (2 x 100 ml).
  • example 49 The free base of example 49 was dissolved in DCM, treated with 1 M HCl in Et 2 O (172 ⁇ l), and evaporated in vacuo. The residue was dissolved in DCM and the salt precipitated by addition of diethyl ether and hexane. The precipitate was filtered off, washed with hexane and diethyl ether, and dried in vacuo at room temperature for 2 h. The product was obtained as a white solid.
  • example 50 The free base of example 50 was dissolved in DCM, treated with 1 M HCl in Et 2 O (44 ⁇ l), and evaporated in vacuo. The residue was dissolved in DCM and the salt precipitated by addition of diethyl ether and hexane. The precipitate was filtered off, washed with hexane and diethyl ether, and dried in vacuo at room temperature for 2 h. The product was obtained as a white solid.
  • the purified product was dissolved in DCM, treated with 1 M HCl in Et 2 O (106 ⁇ l), and the resulting suspension was diluted with diethyl ether and hexane. The precipitate was filtered off, washed with hexane and diethyl ether, and dried in vacuo at 40°C for 2 h. The product was obtained as a white solid.
  • the purified product was dissolved in DCM, treated with 1 M HCl in Et 2 O (96 ⁇ l), and the resulting suspension was diluted with diethyl ether and hexane. The precipitate was filtered off, washed with hexane and diethyl ether, and dried in vacuo at 40°C for 2 h. The product was obtained as a white solid.
  • the crude product was purified with flash chromatography.
  • the free base was dissolved in ethyl acetate (2 ml) and 1 M HCl in diethyl ether (200 ⁇ l) was added.
  • the product was precipitated by addition of hexane (20 ml). The precipitate was filtered off and dried in vacuo over P 2 O 5 .
  • the crude product was purified with flash chromatography.
  • the free base was dissolved in ethyl acetate (2 ml) and 1 M HCl in diethyl ether (200 ⁇ l) was added.
  • the product was precipitated by addition of hexane (20 ml).- The precipitate was filtered off and dried in vacuo over P 2 O 5 .
  • the purified product was dissolved in DCM, treated with 1 M HCl in Et 2 O (108 ⁇ l), and the resulting suspension was diluted with diethyl ether and hexane. The precipitate was filtered off, washed with hexane and diethylether, and dried in vacuo at 40°C for 2 h. The product was obtained as an off-white solid.
  • the purified product was dissolved in DCM, treated with 1 M HCI in Et 2 O (60 ⁇ l), and the resulting suspension was diluted with diethyl ether and hexane. The precipitate was filtered off, washed with hexane and diethyl ether, and dried in vacuo at 40°C for 2 h. The product was obtained as a white solid.
  • N-(Diphenylmethylene) glycine ethyl ester (9.29 g), 1-(bromomethyl)-4-chloro-2-fluorobenzene (8.63 g) and benzyltriethylammonium chloride (TEBAC) (7.91 g) were dissolved in DCM (100 ml) and 10% aqueous KOH (91 ml) was added. The resulting two-phase mixture was stirred at room temperature for 24 hours. Then the organic layer was separated and concentrated. The residue was taken up in diethyl ether (200 ml) and washed with water (150 ml) followed by brine (100 ml) and the organic layer was dried over Na 2 SO 4 . The solvent was removed under reduced pressure. The product was purified by flash chromatography.
  • the suspension was put in the fridge overnight, filtered, and the product, a white solid, was rinsed with water and diethyl ether. The filtrate was evaporated again to dryness and water (10 ml) was added. The suspension was put in the fridge overnight, filtered and the second batch of product was rinsed with water and diethyl ether. The solids from the two batches were combined and dried in vacuo.
  • Racemic intermediate 80c (313 mg) was dissolved in Tris-maleate buffer (26 ml, pH 7.8) containing 0.1 M KCl. To this solution was added L-amino acid oxidase (Sigma Type 1, activity 0.33 units/mg; 10 mg) and catalase (1 mg). After 84 h, the reaction mixture was brought to pH 7 with 0.5 N HCl and purified by ion-exchange chromatography over Dowex 50, eluting the amino acid with 1 N ammonia. The solvent was removed under reduced pressure and the product was dried in vacuo at room temperature over P 2 O 5 overnight.
  • Tris-maleate buffer 26 ml, pH 7.8 containing 0.1 M KCl.
  • L-amino acid oxidase Sigma Type 1, activity 0.33 units/mg; 10 mg
  • catalase 1 mg
  • aqueous phase was acidified to pH 2 using 1 N, aqueous hydrochloric acid and extracted with ethyl acetate (3 x 40 ml). The combined organic layer was then dried over Na 2 SO 4 . filtered and concentrated in vacuo.
  • the purified product was dissolved in ethyl acetate (2 ml), treated with 1 M HCl in Et 2 O (200 ⁇ l), and the resulting suspension was diluted with hexane (20 ml). The precipitate was filtered off, washed with hexane and diethyl ether, and dried in vacuo at room temperature over P 2 O 5 overnight. The product was obtained as a white solid.
  • Phosphorous tribromide (735 ⁇ l) was added to a stirred solution of 4-chloro-2-methylbenzyl alcohol (3.5 g) in toluene (30 ml) at 40°C. The solution was heated to 100°C for 30 min, and the reaction was cooled to ambient temperature. The liquid was decanted and washed with water (2 x 50 ml) and brine (50 ml). The combined aqueous layer was extracted with diethyl ether (70 ml) and the combined organic layer was evaporated to yield a semisolid residue. The residue was dissolved in diethyl ether (350 ml) and washed with water (2 x 100 ml) and brine (100 ml). The organic phase was dried over Na 2 SO 4 , filtered and evaporated to yield a light yellow oil.
  • N-(Diphenylmethylene) glycine ethyl ester (5.27 g), intermediate 104a) (4.81 g) and benzyltriethylammonium chloride (TEBAC) (4.49 g) were dissolved in DCM (52 ml) and 10% aqueous KOH (52 ml) was added. The resulting two-phase mixture was stirred at room temperature for 24 h. The organic layer was separated and concentrated. The residue was taken up with diethyl ether (125 ml) and washed with water (100 ml) followed by brine (100 ml) and dried over Na 2 SO 4 . The solvent was removed to give the crude product as a yellow oil. The crude product was purified by flash column chromatography.
  • the combined organic layer was dried over Na 2 SO 4 , filtered and the solvent was removed under reduced pressure to give a yellow oil.
  • the crude product was dissolved in THF (20 ml) and 1 N aqueous sodium hydroxide (12.1 ml) was added portionwise at 0°C. The reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure and water (50 ml) was added to the residue. The aqueous phase was washed with diethyl ether (2 x 100 ml) and DCM (2 x 100 ml) and then neutralized to pH 7 with 5N aqueous HCl (2 ml). The aqueous phase was evaporated under reduced pressure to yield the product as a white solid.
  • reaction mixture was acidified to pH 2 using 1N aqueous hydrochloric acid (1.3 ml) and extracted with DCM (3 x 20 ml). The combined organic layer was dried over Na 2 SO 4 , filtered and concentrated in vacuo to give a colorless wax.
  • the crude product was purified by column chromatography.
  • the purified product was dissolved in EtOAc (400 ⁇ l), treated with 0.1 M citric acid in EtOH (721 ⁇ l), and hexane (8.0 ml). The precipitate was filtered off, washed with hexane (1.0 ml) and dried in vacuo over P 2 O 5 at room temperature overnight.
  • intermediate 121e 50 mg
  • intermediate 121b ⁇ 104 mg in 2 ml water/THF
  • the reaction mixture was stirred at room temperature overnight.
  • the reaction mixture was evaporated in vacuo.
  • the residue was redissolved in EtOAc and the organic layer was washed with sat. Na 2 CO 3 . water and brine.
  • the aqueous layers were extracted with EtOAc.
  • the combined organic layer was dried over Na 2 SO 4 and evaporated in vacuo to dryness.
  • the crude product was purified by flash chromatography following purification with preparative HPLC MS.
  • a membrane binding assay is used to identify competitive inhibitors of fluorescence labeled NDP-alpha-MSH binding to HEK293 cell membrane preparations expressing human melanocortin receptors.
  • test compound or unlabeled NDP-alpha-MSH is dispensed at varying concentrations to a 384 well microtiter plate. Fluorescence labeled NDP-alpha-MSH is dispensed at a single concentration, followed by addition of membrane preparations. The plate is incubated for 5 h at room temperature.
  • the degree of fluorescence polarization is determined with a fluorescence polarization microplate reader.
  • Agonistic activity of human melanocortin receptors is determined in a homogeneous membrane based assay. Competition between unlabeled cAMP and a fixed quantity of fluorescence labeled cAMP for a limited number of binding sites on a cAMP specific antibody is revealed by fluorescence polarization.
  • test compound or unlabeled NDP-alpha-MSH is dispensed at varying concentrations to a 384 well microtiter plate.
  • Membrane preparations from HEK293 cells expressing the human melanocortin receptors are added.
  • an appropriate amount of ATP, GTP and the cAMP antibody is added and the plate is further incubated before the fluorescence labeled cAMP conjugate is dispensed.
  • the plate is incubated for 2 h at 4°C before it is read on a fluorescence polarization microplate reader.
  • the amount of cAMP produced as a response to a test compound is compared to the production of cAMP resulting from stimulation with NDP-alpha-MSH.
  • Food intake in rats is measured after i.p. or p.o. administration of the test compound (see e.g. A.S. Chen et al. Transgenic Res 2000 Apr; 9(2):145-154 ).
  • LPS lipopolysaccharide
  • This conditioning takes about 4 days. Day 1, the animals are placed in a darkened restrainer and left for 15 - 30 minutes. Day 2, the animals are restrained in a supine position in the restrainer for 15 - 30 minutes. Day 3, the animals are restrained in the supine position with the penile sheath retracted for 15 - 30 minutes. Day 4, the animals are restrained in the supine position with the penile sheath retracted until penile responses are observed. Some animals require additional days of conditioning before they are completely acclimated to the procedures; non-responders are removed from further evaluation. After any handling or evaluation, animals are given a treat to ensure positive reinforcement.
  • Rats are gently restrained in a supine position with their anterior torso placed inside a cylinder of adequate size to allow for normal head and paw grooming.
  • the diameter of the cylinder is approximately 8 cm.
  • the lower torso and hind limbs are restrained with a nonadhesive material (vetrap).
  • An additional piece of vetrap with a hole in it, through which the glans penis will be passed, is fastened over the animal to maintain the preputial sheath in a retracted position.
  • Penile responses will be observed, typically termed ex copula genital reflex tests. Typically, a series of penile erections will occur spontaneously within a few minutes after sheath retraction.
  • the types of normal reflexogenic erectile responses include elongation, engorgement, cup and flip.
  • An elongation is classified as an extension of the penile body.
  • Engorgement is a dilation of the glans penis.
  • a cup is defined as an intense erection where the distal margin of the glans penis momentarily flares open to form a cup.
  • a flip is a dorsiflexion of the penile body.
  • Baseline and or vehicle evaluations are conducted to determine how, and if, an animal will respond. Some animals have a long duration until the first response while others are non-responders altogether. During this baseline evaluation latency to first response, number and type of responses are recorded. The testing time frame is 15 minutes after the first response.
  • test compound After a minimum of 1 day between evaluations, these same animals are administered the test compound at 20 mg/kg and evaluated for penile reflexes. All evaluations are videotaped and scored later. Data are collected and analyzed using paired 2 tailed t-tests to compared baseline and/or vehicle evaluations to drug treated evaluations for individual animals. Groups of a minimum of 4 animals are utilized to reduce variability.
  • mice can be dosed by a number of routes of administration depending on the nature of the study to be performed.
  • the routes of administration includes intravenous (IV), intraperitoneal (IP), subcutaneous (SC) and intracerebral ventricular (ICV).
  • Rodent assays relevant to female sexual receptivity include the behavioral model of lordosis and direct observations of copulatory activity. There is also a urethrogenital reflex model in anesthetized spinally transected rats for measuring orgasm in both male and female rats. These and other established animal models of female sexual dysfunction are described in K.E. McKenna et al, A Model For The Study of Sexual Function In Anesthetized Male And Female Rats, Am. J. Physiol. (Regulatory Integrative Comp. Physiol 30): R1276-R1285, 1991 ; K.E. McKenna et al, Modulation By Peripheral Serotonin of The Threshold For sexual Reflexes In Female Rats, Pharm. Bioch.
  • Example 2 As a specific embodiment of an oral composition of a compound of the present invention, 30 mg of Example 2 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0 hard gelatin capsule.
  • Example 20 As another specific embodiment of an oral composition of a compound of the present invention, 25 mg of Example 20 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0 hard gelatin capsule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (18)

  1. Composé répondant à la formule (I)
    Figure imgb0400
     et les énantiomères, diastéréoisomères, tautomères, solvates, et sels pharmaceutiquement acceptables de celui-ci,
    où
    R1 représente
    -(C(R6)2)l-T, ou
    -O-(C(R6)2)m-T;
    R6 est indépendamment choisi parmi
    H,
    F,
    OH,
    OCH3,
    un groupe alkyle en C1-6, éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN, OH et OCH3, et
    un groupe cycloalkyle en C3-6, éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN, OH et OCH3 ;
    T représente
    NR7R8,
    une fraction morpholine,
    Figure imgb0401
    Figure imgb0402
     ou
    Figure imgb0403
    R7 et R8 sont indépendamment choisis parmi
    H,
    un groupe alkyle en C1-6,
    un groupe alcényle en C2-6,
    un groupe alcynyle en C2-6, et
    un groupe (alkylène en C2-6)-O-(alkyle en C1-6),
    où chaque groupe alkyle, alcényle et alcynyle est éventuellement substitué par un ou plusieurs atomes d'halogène, CN ou OH ;
    R9 est indépendamment choisi parmi
    un halogène,
    CN,
    OH,
    un groupe alkyle en C1-6 éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH, et
    un groupe O-alkyle en C1-6 éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH,
    un groupe (alkylène en C1-6)-O-(alkyle en C1-6) éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH ;
    R10 représente
    H, ou
    un groupe alkyle en C1-6 ;
    R11 est indépendamment choisi parmi
    un halogène,
    CN,
    OH,
    un groupe alkyle en C1-6 éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH,
    un groupe O-alkyle en C1-6 éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH,
    un groupe (alkylène en C1-6)-O-(alkyle en C1-6) éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH,
    -NH2,
    un groupe -NH(alkyle en C1-6), et un groupe -N(alkyle en C1-6)2 ;
    X représente
    CH ou N;
    Y représente
    CH ou N ;
    Z représente
    CH ou N ;
    A représente
    un cycle de 3 à 7 chaînons saturé, insaturé ou aromatique, contenant 0-2 atomes d'azote ;
    R2 est indépendamment choisi parmi
    F,
    Cl,
    CH3, et
    CF3 ;
    R3 représente
    H,
    Cl,
    F, ou
    CH3 ;
    R4 représente
    Cl ou F;
    R5 représente
    Figure imgb0404
    Figure imgb0405
     une fraction morpholine, éventuellement substituée par 1 à 3 substituants R14 identiques ou différents, ou
    NR12R13;
    R12 et R13 sont indépendamment choisis parmi
    un groupe alkyle en C1-6,
    un groupe alcényle en C2-6,
    un groupe alcynyle en C2-6,
    un groupe (alkylène en C2-6)-O-(alkyle en C1-6), et un groupe (alkylène en C2-6)-N-(alkyle en C1-6)2 ;
    R14 représente
    un groupe alkyle en C1-6,
    un groupe (alkylène en C1-6)-O-(alkyle en C1-6), un groupe (alkylène en C1-6)-OH,
    un groupe (alkylène en C1-6)-NH2,
    un groupe (alkylène en C1-6)-NH-(alkyle en C1-6), ou un groupe (alkylène en C1-6)-N(alkyle en C1-6)2 ;
    I vaut 1, 2, 3, ou 4 ;
    m vaut 0, 1, 2, 3, ou 4 ;
    n vaut 0, 1, 2, 3, ou 4 ;
    o vaut 0, 1, ou 2 ;
    p vaut 0, 1, 2, 3, ou 4 ;
    q vaut 0, 1, 2, ou 3 ;
    r vaut 0, 1, 2, 3, ou 4 et
    s vaut 1, ou 2.
  2. Composé selon la revendication 1 répondant à la formule (I')
    Figure imgb0406
     dans laquelle R1, R2, R3, R4, R5 et n sont tels que définis dans la revendication 1.
  3. Composé selon la revendication 1 ou 2, dans lequel
    R1 représente
    -(CH2)l-T,
    -O-(CH2)m-T ;
    T représente
    NR7R8,
    une fraction morpholine,
    Figure imgb0407
    Figure imgb0408
    R7 et R8 sont indépendamment choisis parmi
    un groupe alkyle en C1-6,
    un groupe alcényle en C2-6,
    un groupe alcynyle en C2-6, et
    un groupe (alkylène en C2-6)-O-(alkyle en C1-6) ;
    R9 est indépendamment choisi parmi
    un halogène,
    CN,
    OH,
    un groupe alkyle en C1-6 éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH, et
    un groupe O-alkyle en C1-6 éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH ;
    X représente
    CH ou N ;
    Y représente
    CH ou N ;
    Z représente
    CH ou N ;
    R2 est indépendamment choisi parmi
    F,
    Cl,
    CH3, et
    CF3 ;
    R3 représente
    H,
    Cl, ou
    CH3 ;
    R4 représente
    CI ;
    R5 représente
    Figure imgb0409
    Figure imgb0410
     une fraction morpholine, éventuellement substituée par 1 à 3 substituants R14 identiques ou différents, ou
    NR12R13;
    R11 est indépendamment choisi parmi
    un halogène,
    CN,
    OH,
    un groupe alkyle en C1-6 éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH,
    un groupe O-alkyle en C1-6 éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH,
    un groupe (alkylène en C1-6)-O-(alkyle en C1-6) éventuellement substitué par 1 à 3 substituants choisis parmi un halogène, CN et OH,
    -NH2,
    un groupe -NH(alkyle en C1-6), et
    un groupe -N(alkyle en C1-6)2 ;
    R12 et R13 sont indépendamment choisis parmi
    un groupe alkyle en C1-6,
    un groupe alcényle en C2-6,
    un groupe alcynyle en C2-6,
    un groupe (alkylène en C2-6)-O-(alkyle en C1-6) ;
    R14 représente
    un groupe alkyle en C1-6,
    un groupe (alkylène en C1-6)-O-(alkyle en C1-6), un groupe (alkylène en C1-6)-OH,
    un groupe (alkylène en C1-6)-NH2,
    un groupe (alkylène en C1-6)-NH-(alkyle en C1-6), ou
    un groupe (alkylène en C1-6)-N(alkyle en C1-6)2;
    A représente
    un cycle de 3 à 7 chaînons saturé, insaturé ou aromatique, contenant 0-2 atomes d'azote ;
    I vaut 1, 2, 3, ou 4 ;
    m vaut 2, 3, ou 4 ;
    n vaut 0, 1, 2, 3, ou 4 ;
    o vaut 0, 1, ou 2 ;
    p vaut 0, 1, 2, 3, ou 4 ;
    q vaut 0, 1, 2, ou 3 ;
    r vaut 0, 1, 2, 3, ou 4 ; et
    s vaut 1, ou 2 ;
  4. Composé selon l'une quelconque des revendications 1 à 3, dans lequel au moins un des R7 et R8 est choisi parmi
    un groupe alcényle en C2-6,
    un groupe alcynyle en C2-6, et
    un groupe (alkylène en C2-6)-O-(alkyle en C1-6).
  5. Composé selon l'une quelconque des revendications 1 à 4, dans lequel
    R2 représente
    F ou Cl, et
    R3 représente
    Cl.
  6. Composé selon l'une quelconque des revendications 1 à 5 dans lequel
    I vaut 2 ou 3, et
    m vaut 2 ou 3.
  7. Composé selon l'une quelconque des revendications 1 à 6 en tant que médicament.
  8. Utilisation du composé selon l'une quelconque des revendications 1 à 6 pour la préparation d'un médicament destiné au traitement ou à la prophylaxie de troubles, maladies ou affections sensibles à l'inactivation ou à l'activation du récepteur de la mélanocortine de type 4 chez un mammifère.
  9. Utilisation selon la revendication 8 pour la préparation d'un médicament destiné au traitement ou à la prophylaxie de la cachexie d'origine cancéreuse.
  10. Utilisation selon la revendication 8 pour la préparation d'un médicament destiné au traitement ou à la prophylaxie de la fonte musculaire.
  11. Utilisation selon la revendication 8 pour la préparation d'un médicament destiné au traitement ou à la prophylaxie de l'anorexie.
  12. Utilisation selon la revendication 8 pour la préparation d'un médicament destiné au traitement ou à la prophylaxie de l'anxiété et/ou de la dépression.
  13. Utilisation selon la revendication 8 pour la préparation d'un médicament destiné au traitement ou à la prophylaxie de l'obésité.
  14. Utilisation selon la revendication 8 pour la préparation d'un médicament destiné au traitement ou à la prophylaxie du diabète sucré.
  15. Utilisation selon la revendication 8 pour la préparation d'un médicament destiné au traitement ou à la prophylaxie de la dysfonction sexuelle chez le mâle ou la femelle.
  16. Utilisation selon la revendication 8 pour la préparation d'un médicament destiné au traitement ou à la prophylaxie de la dysfonction érectile.
  17. Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1 à 6 et un véhicule pharmaceutiquement acceptable.
  18. Composé selon l'une quelconque des revendications 1 à 6 destiné à être utilisé dans le traitement ou la prophylaxie de la cachexie d'origine cancéreuse, de la fonte musculaire, de l'anorexie, de l'anxiété et/ou de la dépression, de l'obésité, du diabète sucré, de la dysfonction sexuelle chez le mâle ou la femelle et/ou de la dysfonction érectile.
EP07724056A 2006-04-07 2007-04-05 Dérivés de phénylpipéridine substitués en tant que modulateurs du récepteur de la mélanocortine-4 Not-in-force EP2004604B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07724056A EP2004604B1 (fr) 2006-04-07 2007-04-05 Dérivés de phénylpipéridine substitués en tant que modulateurs du récepteur de la mélanocortine-4

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79049306P 2006-04-07 2006-04-07
EP06007416A EP1842846A1 (fr) 2006-04-07 2006-04-07 Dérivés de phénylpipéridine comme modulateurs du récepteur de la mélanocortine-4
EP07724056A EP2004604B1 (fr) 2006-04-07 2007-04-05 Dérivés de phénylpipéridine substitués en tant que modulateurs du récepteur de la mélanocortine-4
PCT/EP2007/003115 WO2007115798A1 (fr) 2006-04-07 2007-04-05 Dérivés de phénylpipéridine substitués en tant que modulateurs du récepteur de la mélanocortine-4

Publications (2)

Publication Number Publication Date
EP2004604A1 EP2004604A1 (fr) 2008-12-24
EP2004604B1 true EP2004604B1 (fr) 2010-12-01

Family

ID=36741407

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06007416A Withdrawn EP1842846A1 (fr) 2006-04-07 2006-04-07 Dérivés de phénylpipéridine comme modulateurs du récepteur de la mélanocortine-4
EP07724056A Not-in-force EP2004604B1 (fr) 2006-04-07 2007-04-05 Dérivés de phénylpipéridine substitués en tant que modulateurs du récepteur de la mélanocortine-4

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP06007416A Withdrawn EP1842846A1 (fr) 2006-04-07 2006-04-07 Dérivés de phénylpipéridine comme modulateurs du récepteur de la mélanocortine-4

Country Status (8)

Country Link
US (1) US20110086836A1 (fr)
EP (2) EP1842846A1 (fr)
JP (1) JP2009532405A (fr)
AT (1) ATE490239T1 (fr)
CA (1) CA2648335A1 (fr)
DE (1) DE602007010914D1 (fr)
ES (1) ES2360883T3 (fr)
WO (1) WO2007115798A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019100A1 (fr) * 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Dérivés substitués d'hétéroarylpipéridine en tant que modulateurs du récepteur de la mélanocortine-4
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2072050A1 (fr) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Composés à effet anti-émétique
FR2932479A1 (fr) * 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2937868B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Composes antagonistes des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
FR2937973B1 (fr) * 2008-11-04 2010-11-05 Galderma Res & Dev Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
EP2210885A1 (fr) 2009-01-14 2010-07-28 Santhera Pharmaceuticals (Schweiz) AG Dérivés substitués d'hétéroarylpipéridine en tant que modulateurs du récepteur de la mélanocortine-4
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
JP5869666B2 (ja) * 2011-04-25 2016-02-24 エルジー エレクトロニクス インコーポレイティド イントラ予測方法とそれを利用した符号化器及び復号化器
JP6227673B2 (ja) * 2013-12-17 2017-11-08 ステラファーマ株式会社 ２−フルオロ−４−ボロノ−ｌ−フェニルアラニンの製造方法および２−フルオロ−４−ボロノ−ｌ−フェニルアラニンの前駆体
MA42707A (fr) * 2015-09-02 2018-07-04 Selux Diagnostics Inc Systèmes et procédés de détection multiplexée de biomarqueurs
WO2017043626A1 (fr) * 2015-09-11 2017-03-16 株式会社カネカ Procédé de production d'un dérivé 4-carbamoyl-2,6-diméthylphénylalanine optiquement actif
CN109879766A (zh) * 2019-03-02 2019-06-14 台州保灵药业有限公司 一种3-(nn-二甲基）氨基丁醇的合成方法
EP3965770A4 (fr) 2019-05-09 2023-01-18 The Feinstein Institutes for Medical Research Composés destinés à être utilisés dans la synthèse de peptidomimétiques
AU2020270125A1 (en) 2019-05-09 2021-11-25 The Feinstein Institutes For Medical Research Thiosemicarbazates and uses thereof
CA3139109A1 (fr) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Antagoniste de hmgb1
US11883461B2 (en) 2019-05-09 2024-01-30 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
WO2020227588A1 (fr) * 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Agents peptidomimétiques, synthèse et utilisations de ceux-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
WO2004024720A1 (fr) * 2002-09-11 2004-03-25 Merck & Co., Inc. Derives d'uree de piperazine utilises comme agonistes des recepteurs de melanocortine-4
KR20050045927A (ko) * 2003-11-12 2005-05-17 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제

Also Published As

Publication number Publication date
WO2007115798A1 (fr) 2007-10-18
ATE490239T1 (de) 2010-12-15
ES2360883T3 (es) 2011-06-10
US20110086836A1 (en) 2011-04-14
JP2009532405A (ja) 2009-09-10
EP2004604A1 (fr) 2008-12-24
DE602007010914D1 (de) 2011-01-13
CA2648335A1 (fr) 2007-10-18
EP1842846A1 (fr) 2007-10-10

Similar Documents

Publication Publication Date Title
EP2004604B1 (fr) Dérivés de phénylpipéridine substitués en tant que modulateurs du récepteur de la mélanocortine-4
EP2176250B1 (fr) Dérivés d'hétéroarylpipéridine substitués utilisés comme modulateurs du récepteur 4 de la mélanocortine
JP4104983B2 (ja) メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体
JP2010522224A (ja) メラノコルチン−４受容体アンタゴニストとしての置換イミダゾピリジン誘導体
US20070155783A1 (en) Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators
AU2004222090B2 (en) Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
EP1538159A1 (fr) Dérivés de N-benzyl-lactam comme agonistes du récepteur melanocortine-4
WO2007096186A1 (fr) Dérivés de phénylpipéridine substituée servant de modulateurs du récepteur de la mélanocortine-4.
EP2210885A1 (fr) Dérivés substitués d'hétéroarylpipéridine en tant que modulateurs du récepteur de la mélanocortine-4
EP2103614A1 (fr) Dérivés d'imidazopyrimidine, d'imidazopyrazine et d' imidazopyridazine substitués en tant que modulateur de récepteur de la mélanocortine-4
EP2020405A1 (fr) Dérivés substitués d'aryle ou d'hétéroarylpipéridine en tant que modulateurs du récepteur de la mélanocortine-4
EP1460070B1 (fr) Dérivés substitués de la pipéridine et la pipérazine comme modulateurs du récepteur de la melanocortine-4
EP1603912B1 (fr) Derives a substitution piperidine et piperazine agissant comme modulateurs du recepteur de la melanocortine-4
EP1826201A1 (fr) Dérivés substitués de la phenylpipéridine comme modulateurs du récepteur de la melanocortine-4

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: SANTHERA PHARMACEUTICALS (SCHWEIZ) AG

REF Corresponds to:

Ref document number: 602007010914

Country of ref document: DE

Date of ref document: 20110113

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20101201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20101201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110301

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2360883

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20110610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110401

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110401

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

26N No opposition filed

Effective date: 20110902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110405

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007010914

Country of ref document: DE

Effective date: 20110902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20111230

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111101

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110502

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007010914

Country of ref document: DE

Effective date: 20111101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110405

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110405

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20120524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110406

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101201